MRSN

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).

Wall Street analysts forecast MRSN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRSN is 30.75 USD with a low forecast of 30.75 USD and a high forecast of 30.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Mersana Therapeutics Inc revenue for the last quarter amounts to 11.01M USD, decreased -12.61 % YoY.

Mersana Therapeutics Inc. EPS for the last quarter amounts to -1.51 USD, decreased -35.47 % YoY.

Mersana Therapeutics Inc (MRSN) has 102 emplpoyees as of December 15 2025.

Today MRSN has the market capitalization of 141.71M USD.